| | Date | CD4 (cells/μl) | Viral load (cp/ml) | Regimen | Biochemistry |
| | 05/2017 | 13 | 398.000 | Darunavir/ritonavir, lamivudine | Glucose: 93 mg/dL, total cholesterol: 184 mg/dL, eGFR: 7 ml/min, GOT: 26 IU/ml, GPT: 9 IU/ml, PA: 102 IU/ml, GGT: 41 IU/ml, Hb: 6.6 g/dl, platelets: 82 × 103/μL, weight: 45 kg, PD | | 06/2017 | 47 | 1430 | Induction with foscarnet [9] followed by SC enfuvirtide, maraviroc, tenofovir, lamivudine, high dose darunavir/r, high dose dolutegravir | Glucose: NA, total cholesterol: NA, eGFR: 7 ml/min, GOT: 16 IU/ml, GPT: 18 IU/ml, PA: 289 IU/ml, GGT: 112 IU/ml, Hb: 9.5 g/dl, platelets: 283 × 103/μL, weight: 45.4 kg, PD | | 12/2017 | 379 | <20 | SC enfuvirtide, maraviroc, tenofovir, lamivudine, high dose darunavir/r, high dose dolutegravir | Glucose: 224 mg/dL total cholesterol: 139 mg/dL, eGFR: 6 ml/min, GOT: 12 IU/ml, GPT: 160 IU/ml, PA: 235 IU/ml, GGT: 55 IU/ml, Hb: 9.20 g/dl, platelets: 252 × 103/μL, weight: NA, PD | | 04/2018 | 348 | <20 | Idem stop tenofovir 12/2018 | Glucose: 130 mg/dL, total cholesterol: 134 mg/dL, eGFR: 5 ml/min, GOT: 10 IU/ml, GPT: 9 IU/ml, PA: 209 IU/ml, GGT: 35 IU/ml, Hb: 10.2 g/dl, platelets: 2 64 × 103/μL, weight: 52 kg, PD | | 09/2019 | 582 | <20 | SC enfuvirtide, maraviroc, lamivudine, high dose darunavir/r, high dose dolutegravir | Glucose: 111 mg/dL, total cholesterol: NA, eGFR: 5 ml/min, GOT: 17 IU/ml, GPT: 17 IU/ml, PA: 689 IU/ml, GGT: 41 IU/ml, Hb: 9.3 g/dl, platelets: 287 × 103/μL, weight: 51.9 kg, PD | | 04/2020 | 570 | <20 | SC enfuvirtide, maraviroc, lamivudine, high dose darunavir/r, high dose dolutegravir | Glucose: 98 mg/dL, total cholesterol: 176 mg/dL, eGFR: 6 ml/min, GOT: 10 IU/ml, GPT: 6 IU/ml, PA: 726 IU/ml, GGT: 19 IU/ml, Hb:10.3 g/dl, platelets: 270 × 103/μL, weight: 39.5 kg, PD | | 09/2020 | 456 | 37 | Stop enfuvirtide 02/2020 | HD | | 03/2021 | 591 | 20200 | Nonadherence, resumption of same treatment + counselling | 03/2021 genotypic resistance testing: results shown above | | 10/2021 | 429 | 338 | Maraviroc, lamivudine, high dose darunavir/r, high dose dolutegravir | Glucose: 130 mg/dL, Hb A1c: 6.1%, total cholesterol: 98 mg/dL, triglyceride:84 mg/dL, eGFR: 4 ml/min, GOT: 28 IU/ml, GPT: 17 IU/ml, PA: 105 IU/ml, GGT: 17 IU/ml, Hb: 10.6 g/dl, platelets: 178 × 103/μL,weight: 48.9 kg, HD | | 06/2022 | 486 | <20 | LEN: oral loading dose over 8 days then 2 subcutaneous injections of 463.5 mg/1.5 mL biannually + FTR: 600 mg BID + 3TC: 75 mg QD | Glucose: 82 mg/dL, total cholesterol: 117 mg/dL, triglyceride: 74 mg/dL, eGFR:4 ml/min, GOT: 15 IU/ml, GPT: 11 IU/ml, PA: 112 IU/ml, GGT: 14 IU/ml, Hb: 11.8 g/dl, platelets: 244 × 103/μL,weight: 53.5 kg, HD | | 12/2022 | 388 | <20 | LEN + FTR + 3TC | Glucose: 196 mg/dL, Hb A1c: 5.4%, total cholesterol: 115 mg/dL, Triglyceride: 58 mg/dL, eGFR: 4 ml/min, GOT: 18 IU/ml, GPT: 14 IU/ml, PA: 126 IU/ml, GGT: 15 IU/ml, Hb: 12 g/dl, platelets: 149 × 103/μL, weight: 53.5 kg, HD | | 07/2023 | 392 | <20 | LEN + FTR + 3TC | Glucose: 190 mg/dL, HbA1c: 5.3%, total cholesterol: 105 mg/dL, triglyceride: 51 mg/dL, eGFR: 3 ml/min, GOT: 17 IU/ml, GPT: 13 IU/ml, PA: 152 IU/ml, GGT: 21 IU/ml, Hb: 12.5 g/dl, platelets: 195 × 103/μL, weight: 52.5 kg, HD | | 08/2023 | | | LEN + FTR + 3TC | Renal transplantation |
|
|
